Projects per year
Personal profile
Area of Expertise
Glaucoma is an eye disease commonly associated with an increase in intraocular pressure, afflicting nearly 3 million Americans and 70 million people world-wide. Current therapies are aimed at lowering intraocular pressure, however, damage to the optic nerve continues to occur despite these treatments. There is a pressing need for adjunct therapies aimed at protecting the optic nerve from further damage.
My laboratory research focuses on the development of strategies for neuroprotection in glaucoma. Specifically, we are testing various small molecules and adeno-associated viral gene therapies for their ability to attenuate neurodegeneration in animal models of glaucoma. We also aim to unravel cellular and molecular mechanisms underlying the pathophysiology of glaucoma.
Concepts/techniques: We carry out these studies using in vitro rat primary retinal ganglion cell cultures, ex vivo adult rat retinal explants, and various in vivo rodent models of glaucoma. We use visual function tests including pattern ERG and optomotor test to determine the efficacy of clinically relevant experimental pharmacotherapies.
Our ongoing studies have the potential to develop novel therapeutic agents for neuroprotection in glaucoma.
My laboratory research focuses on the development of strategies for neuroprotection in glaucoma. Specifically, we are testing various small molecules and adeno-associated viral gene therapies for their ability to attenuate neurodegeneration in animal models of glaucoma. We also aim to unravel cellular and molecular mechanisms underlying the pathophysiology of glaucoma.
Concepts/techniques: We carry out these studies using in vitro rat primary retinal ganglion cell cultures, ex vivo adult rat retinal explants, and various in vivo rodent models of glaucoma. We use visual function tests including pattern ERG and optomotor test to determine the efficacy of clinically relevant experimental pharmacotherapies.
Our ongoing studies have the potential to develop novel therapeutic agents for neuroprotection in glaucoma.
Education/Academic qualification
MS in Biochemistry & Genetics, University of Łódź
PhD in Microbiology, University of Łódź
Fingerprint
Dive into the research topics where Dorota Stankowska is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma
Stankowska, D. & ACHARYA, S.
1/09/21 → 31/08/22
Project: Research
-
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma
Stankowska, D. & ACHARYA, S.
1/09/20 → 31/08/21
Project: Research
-
-
Mechanisms Underlying Endothelin Mediated Neurodegeneration in Glaucoma
Krishnamoorthy, R., He, S. & Stankowska, D.
1/09/17 → 31/08/20
Project: Research
-
Neuroprotective targets of transcription factor Brn3b (For: Alexis Seibert)
5/06/17 → 31/05/18
Project: Research
-
Involvement of c-Jun N-terminal kinase 2 (JNK2) in endothelin-1 (ET-1) mediated neurodegeneration of retinal ganglion cells
Kodati, B., Stankowska, D. L., Krishnamoorthy, V. R. & Krishnamoorthy, R. R., May 2021, In: Investigative Ophthalmology and Visual Science. 62, 6, 13.Research output: Contribution to journal › Article › peer-review
Open Access -
Nanoencapsulated hybrid compound sa-2 with long-lasting intraocular pressure–lowering activity in rodent eyes
Stankowska, D. L., Millar, J. C., Kodati, B., Behera, S., Chaphalkar, R. M., Nguyen, T., Nguyen, K. T., Krishnamoorthy, R. R., Ellis, D. Z. & Acharya, S., 2021, In: Molecular vision. 27, p. 37-49 13 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Endothelin-1 Mediated Decrease in Mitochondrial Gene Expression and Bioenergetics Contribute to Neurodegeneration of Retinal Ganglion Cells
Chaphalkar, R. M., Stankowska, D. L., He, S., Kodati, B., Phillips, N., Prah, J., Yang, S. & Krishnamoorthy, R. R., 1 Dec 2020, In: Scientific Reports. 10, 1, 3571.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Kynurenic acid protects against ischemia/reperfusion-induced retinal ganglion cell death in mice
Nahomi, R. B., Nam, M. H., Rankenberg, J., Rakete, S., Houck, J. A., Johnson, G. C., Stankowska, D. L., Pantcheva, M. B., Maclean, P. S. & Nagaraj, R. H., 1 Mar 2020, In: International journal of molecular sciences. 21, 5, 1795.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Correction: Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma (Cell Death Discovery, (2019), 5, 1, (112), 10.1038/s41420-019-0194-2)
Stankowska, D. L., Nam, M. H., Nahomi, R. B., Chaphalkar, R. M., Nandi, S. K., Fudala, R., Krishnamoorthy, R. R. & Nagaraj, R. H., 1 Dec 2019, In: Cell Death Discovery. 5, 1, 122.Research output: Contribution to journal › Comment/debate
Open Access